1060 related articles for article (PubMed ID: 34111274)
1. Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study.
Benfield T; Bodilsen J; Brieghel C; Harboe ZB; Helleberg M; Holm C; Israelsen SB; Jensen J; Jensen TØ; Johansen IS; Johnsen S; Lindegaard B; Lundgren J; Meyer CN; Mohey R; Pedersen LM; Nielsen H; Nielsen SL; Obel N; Omland LH; Podlekareva D; Poulsen BK; Ravn P; Sandholdt H; Starling J; Storgaard M; Søborg C; Søgaard OS; Tranborg T; Wiese L; Christensen HR
Clin Infect Dis; 2021 Dec; 73(11):2031-2036. PubMed ID: 34111274
[TBL] [Abstract][Full Text] [Related]
2. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
[TBL] [Abstract][Full Text] [Related]
3. Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone.
Leding C; Bodilsen J; Brieghel C; Harboe ZB; Helleberg M; Holm C; Israelsen SB; Jensen J; Jensen TØ; Johansen IS; Johnsen S; Kirk O; Lindegaard B; Meyer CN; Mohey R; Pedersen L; Nielsen H; Nielsen SL; Omland LH; Podlekareva D; Ravn P; Starling J; Storgaard M; Søborg C; Søgaard OS; Tranborg T; Wiese L; Worm SHW; Christensen HR; Benfield T
Infect Dis (Lond); 2023 May; 55(5):351-360. PubMed ID: 36905638
[TBL] [Abstract][Full Text] [Related]
4. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.
Olender SA; Perez KK; Go AS; Balani B; Price-Haywood EG; Shah NS; Wang S; Walunas TL; Swaminathan S; Slim J; Chin B; De Wit S; Ali SM; Soriano Viladomiu A; Robinson P; Gottlieb RL; Tsang TYO; Lee IH; Hu H; Haubrich RH; Chokkalingam AP; Lin L; Zhong L; Bekele BN; Mera-Giler R; Phulpin C; Edgar H; Gallant J; Diaz-Cuervo H; Smith LE; Osinusi AO; Brainard DM; Bernardino JI;
Clin Infect Dis; 2021 Dec; 73(11):e4166-e4174. PubMed ID: 32706859
[TBL] [Abstract][Full Text] [Related]
5. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
Mehta HB; An H; Andersen KM; Mansour O; Madhira V; Rashidi ES; Bates B; Setoguchi S; Joseph C; Kocis PT; Moffitt R; Bennett TD; Chute CG; Garibaldi BT; Alexander GC;
Ann Intern Med; 2021 Oct; 174(10):1395-1403. PubMed ID: 34399060
[TBL] [Abstract][Full Text] [Related]
6. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation.
Padilla S; Polotskaya K; Fernández M; Gonzalo-Jiménez N; de la Rica A; García JA; García-Abellán J; Mascarell P; Gutiérrez F; Masiá M
J Antimicrob Chemother; 2022 Jul; 77(8):2257-2264. PubMed ID: 35534369
[TBL] [Abstract][Full Text] [Related]
8. Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study.
Marrone A; Nevola R; Sellitto A; Cozzolino D; Romano C; Cuomo G; Aprea C; Schwartzbaum MXP; Ricozzi C; Imbriani S; Rinaldi L; Gjeloshi K; Padula A; Ranieri R; Ruosi C; Meo LA; Abitabile M; Cinone F; Carusone C; Adinolfi LE
Clin Infect Dis; 2022 Aug; 75(1):e403-e409. PubMed ID: 35084022
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
[TBL] [Abstract][Full Text] [Related]
11. Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study.
Garibaldi BT; Wang K; Robinson ML; Betz J; Caleb Alexander G; Andersen KM; Joseph CS; Mehta HB; Korwek K; Sands KE; Fisher AM; Bollinger RC; Xu Y
Clin Infect Dis; 2022 Aug; 75(1):e516-e524. PubMed ID: 34910128
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study.
Joo EJ; Ko JH; Kim SE; Kang SJ; Baek JH; Heo EY; Shi HJ; Eom JS; Choe PG; Bae S; Ra SH; Kim DY; Kim BN; Kang YM; Kim JY; Chung JW; Chang HH; Bae S; Cheon S; Park Y; Choi H; Lee E; Lee BY; Park JW; Sohn Y; Heo JY; Kim SH; Peck KR
J Korean Med Sci; 2021 Mar; 36(11):e83. PubMed ID: 33754512
[TBL] [Abstract][Full Text] [Related]
13. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
14. Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy.
Russo P; Tacconelli E; Olimpieri PP; Celant S; Colatrella A; Tomassini L; Palù G
Viruses; 2022 May; 14(6):. PubMed ID: 35746668
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir plus dexamethasone is associated to improvement in the clinical outcome of COVID-19 hospitalized patients regardless of their vaccination status.
Bernal E; García-Villalba E; Pons E; Hernández MD; Báguena C; Puche G; Carter P; Martinez M; Alcaraz A; Tomás C; Muñoz A; Vicente MR; Nuñez ML; Sancho N; Villalba MC; Cano A; Minguela A
Med Clin (Barc); 2023 Aug; 161(4):139-146. PubMed ID: 37100681
[TBL] [Abstract][Full Text] [Related]
16. Optimal Timing of Remdesivir Initiation in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Administered With Dexamethasone.
Wong CKH; Lau KTK; Au ICH; Xiong X; Chung MSH; Lau EHY; Cowling BJ
Clin Infect Dis; 2022 Aug; 75(1):e499-e508. PubMed ID: 34420051
[TBL] [Abstract][Full Text] [Related]
17. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.
Sellers J; Chang J; Jones J; Hintze TD
Pulm Pharmacol Ther; 2023 Feb; 78():102188. PubMed ID: 36603741
[TBL] [Abstract][Full Text] [Related]
18. Mortality comparision in patients receiving either Remdesivir or Remdesivir plus Baricitinib combination in case of moderate to severe COVID-19 Pneumonia: A retrospective study.
Das D; Mukhopadhyay P; Banerjee D
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443520
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021.
Ayodele O; Ren K; Zhao J; Signorovitch J; Jonsson Funk M; Zhu J; Bao Y; Gondek K; Keenan H;
PLoS One; 2021; 16(12):e0261707. PubMed ID: 34962924
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone, dexamethasone + remdesivir in treating moderate to severe COVID-19: retrospective observational cohort study.
Sattoju N; Gattu S; Merugu SS; Anneboina V; Ganapaka SR
J Infect Dev Ctries; 2023 Jul; 17(7):953-960. PubMed ID: 37515802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
